Enhanced Production of EPA-Derived Anti-Inflammatory Metabolites after Oral Administration of a Novel Self-Emulsifying Highly Purified EPA Ethyl Ester Formulation (MND-2119)
Aims: MND-2119 is a novel once-daily dose self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (EPA-E) and is approved as an antihyperlipidemia agent in Japan. It has improved absorption and achieves higher plasma EPA concentrations at Cmax than conventional EPA-E. In th...
Saved in:
| Published in | Journal of Atherosclerosis and Thrombosis Vol. 30; no. 12; pp. 1927 - 1949 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
Japan Atherosclerosis Society
01.12.2023
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1340-3478 1880-3873 1880-3873 |
| DOI | 10.5551/jat.64135 |
Cover
Loading…
| Abstract | Aims: MND-2119 is a novel once-daily dose self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (EPA-E) and is approved as an antihyperlipidemia agent in Japan. It has improved absorption and achieves higher plasma EPA concentrations at Cmax than conventional EPA-E. In the JELIS trial, concomitant use of EPA-E with statin therapy significantly reduced atherosclerotic cardiovascular disease (ASCVD) risks. As a potential mechanism of action of EPA, endogenous formation of EPA-derived anti-inflammatory metabolites is receiving greater attention. This study aims to investigate the endogenous formation of EPA-derived anti-inflammatory metabolites following single and multiple administrations of MND-2119.Methods: Healthy adult male subjects were randomly assigned to a nonintervention (control) group, MND-2119 2-g/day group, MND-2119 4-g/day group, or EPA-E 1.8-g/day group for 7 days (N=8 per group). Plasma fatty acids and EPA-derived metabolites were evaluated. Peripheral blood neutrophils were isolated, and the production of EPA-derived metabolites from in vitro stimulated neutrophils was evaluated.Results: After single and multiple administrations of MND-2119 2 g/day, there were significant increases in plasma EPA concentration, 18-hydroxyeicosapentaenoic acid (18-HEPE), and 17,18-epoxyeicosatetraenoic acid compared with those of EPA-E 1.8 g/day. They were further increased with MND-2119 4 g/day administration. In neutrophils, the EPA concentration in the MND-2119 2-g/day group was significantly higher compared with that in the EPA-E 1.8-g/day group after multiple administration, and 18-HEPE production was positively correlated with EPA concentration. No safety issues were noted.Conclusions: These results demonstrate that MND-2119 increases the plasma and cellular concentrations of EPA and EPA-derived metabolites to a greater extent than conventional EPA-E formulations. |
|---|---|
| AbstractList | Aims: MND-2119 is a novel once-daily dose self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (EPA-E) and is approved as an antihyperlipidemia agent in Japan. It has improved absorption and achieves higher plasma EPA concentrations at Cmax than conventional EPA-E. In the JELIS trial, concomitant use of EPA-E with statin therapy significantly reduced atherosclerotic cardiovascular disease (ASCVD) risks. As a potential mechanism of action of EPA, endogenous formation of EPA-derived anti-inflammatory metabolites is receiving greater attention. This study aims to investigate the endogenous formation of EPA-derived anti-inflammatory metabolites following single and multiple administrations of MND-2119.Methods: Healthy adult male subjects were randomly assigned to a nonintervention (control) group, MND-2119 2-g/day group, MND-2119 4-g/day group, or EPA-E 1.8-g/day group for 7 days (N=8 per group). Plasma fatty acids and EPA-derived metabolites were evaluated. Peripheral blood neutrophils were isolated, and the production of EPA-derived metabolites from in vitro stimulated neutrophils was evaluated.Results: After single and multiple administrations of MND-2119 2 g/day, there were significant increases in plasma EPA concentration, 18-hydroxyeicosapentaenoic acid (18-HEPE), and 17,18-epoxyeicosatetraenoic acid compared with those of EPA-E 1.8 g/day. They were further increased with MND-2119 4 g/day administration. In neutrophils, the EPA concentration in the MND-2119 2-g/day group was significantly higher compared with that in the EPA-E 1.8-g/day group after multiple administration, and 18-HEPE production was positively correlated with EPA concentration. No safety issues were noted.Conclusions: These results demonstrate that MND-2119 increases the plasma and cellular concentrations of EPA and EPA-derived metabolites to a greater extent than conventional EPA-E formulations. MND-2119 is a novel once-daily dose self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (EPA-E) and is approved as an antihyperlipidemia agent in Japan. It has improved absorption and achieves higher plasma EPA concentrations at C than conventional EPA-E. In the JELIS trial, concomitant use of EPA-E with statin therapy significantly reduced atherosclerotic cardiovascular disease (ASCVD) risks. As a potential mechanism of action of EPA, endogenous formation of EPA-derived anti-inflammatory metabolites is receiving greater attention. This study aims to investigate the endogenous formation of EPA-derived anti-inflammatory metabolites following single and multiple administrations of MND-2119. Healthy adult male subjects were randomly assigned to a nonintervention (control) group, MND-2119 2-g/day group, MND-2119 4-g/day group, or EPA-E 1.8-g/day group for 7 days (N=8 per group). Plasma fatty acids and EPA-derived metabolites were evaluated. Peripheral blood neutrophils were isolated, and the production of EPA-derived metabolites from in vitro stimulated neutrophils was evaluated. After single and multiple administrations of MND-2119 2 g/day, there were significant increases in plasma EPA concentration, 18-hydroxyeicosapentaenoic acid (18-HEPE), and 17,18-epoxyeicosatetraenoic acid compared with those of EPA-E 1.8 g/day. They were further increased with MND-2119 4 g/day administration. In neutrophils, the EPA concentration in the MND-2119 2-g/day group was significantly higher compared with that in the EPA-E 1.8-g/day group after multiple administration, and 18-HEPE production was positively correlated with EPA concentration. No safety issues were noted. These results demonstrate that MND-2119 increases the plasma and cellular concentrations of EPA and EPA-derived metabolites to a greater extent than conventional EPA-E formulations. MND-2119 is a novel once-daily dose self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (EPA-E) and is approved as an antihyperlipidemia agent in Japan. It has improved absorption and achieves higher plasma EPA concentrations at Cmax than conventional EPA-E. In the JELIS trial, concomitant use of EPA-E with statin therapy significantly reduced atherosclerotic cardiovascular disease (ASCVD) risks. As a potential mechanism of action of EPA, endogenous formation of EPA-derived anti-inflammatory metabolites is receiving greater attention. This study aims to investigate the endogenous formation of EPA-derived anti-inflammatory metabolites following single and multiple administrations of MND-2119.AIMSMND-2119 is a novel once-daily dose self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (EPA-E) and is approved as an antihyperlipidemia agent in Japan. It has improved absorption and achieves higher plasma EPA concentrations at Cmax than conventional EPA-E. In the JELIS trial, concomitant use of EPA-E with statin therapy significantly reduced atherosclerotic cardiovascular disease (ASCVD) risks. As a potential mechanism of action of EPA, endogenous formation of EPA-derived anti-inflammatory metabolites is receiving greater attention. This study aims to investigate the endogenous formation of EPA-derived anti-inflammatory metabolites following single and multiple administrations of MND-2119.Healthy adult male subjects were randomly assigned to a nonintervention (control) group, MND-2119 2-g/day group, MND-2119 4-g/day group, or EPA-E 1.8-g/day group for 7 days (N=8 per group). Plasma fatty acids and EPA-derived metabolites were evaluated. Peripheral blood neutrophils were isolated, and the production of EPA-derived metabolites from in vitro stimulated neutrophils was evaluated.METHODSHealthy adult male subjects were randomly assigned to a nonintervention (control) group, MND-2119 2-g/day group, MND-2119 4-g/day group, or EPA-E 1.8-g/day group for 7 days (N=8 per group). Plasma fatty acids and EPA-derived metabolites were evaluated. Peripheral blood neutrophils were isolated, and the production of EPA-derived metabolites from in vitro stimulated neutrophils was evaluated.After single and multiple administrations of MND-2119 2 g/day, there were significant increases in plasma EPA concentration, 18-hydroxyeicosapentaenoic acid (18-HEPE), and 17,18-epoxyeicosatetraenoic acid compared with those of EPA-E 1.8 g/day. They were further increased with MND-2119 4 g/day administration. In neutrophils, the EPA concentration in the MND-2119 2-g/day group was significantly higher compared with that in the EPA-E 1.8-g/day group after multiple administration, and 18-HEPE production was positively correlated with EPA concentration. No safety issues were noted.RESULTSAfter single and multiple administrations of MND-2119 2 g/day, there were significant increases in plasma EPA concentration, 18-hydroxyeicosapentaenoic acid (18-HEPE), and 17,18-epoxyeicosatetraenoic acid compared with those of EPA-E 1.8 g/day. They were further increased with MND-2119 4 g/day administration. In neutrophils, the EPA concentration in the MND-2119 2-g/day group was significantly higher compared with that in the EPA-E 1.8-g/day group after multiple administration, and 18-HEPE production was positively correlated with EPA concentration. No safety issues were noted.These results demonstrate that MND-2119 increases the plasma and cellular concentrations of EPA and EPA-derived metabolites to a greater extent than conventional EPA-E formulations.CONCLUSIONSThese results demonstrate that MND-2119 increases the plasma and cellular concentrations of EPA and EPA-derived metabolites to a greater extent than conventional EPA-E formulations. |
| ArticleNumber | 64135 |
| Author | Naoe, Satoko Arita, Makoto Yano, Takashi Mori, Takuya Kanda, Shingo Miyoshi, Toru Ito, Hiroshi Wakabayashi, Hiroyuki |
| Author_xml | – sequence: 1 fullname: Wakabayashi, Hiroyuki organization: Medical Affairs Department, Mochida Pharmaceutical Co., Ltd – sequence: 1 fullname: Arita, Makoto organization: Division of Physiological Chemistry and Metabolism, Graduate School of Pharmaceutical Sciences, Keio University – sequence: 1 fullname: Mori, Takuya organization: Clinical Research Department, Mochida Pharmaceutical Co., Ltd – sequence: 1 fullname: Ito, Hiroshi organization: Department of General Internal Medicine 3, Kawasaki Medical School – sequence: 1 fullname: Miyoshi, Toru organization: Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 1 fullname: Naoe, Satoko organization: Medical Affairs Department, Mochida Pharmaceutical Co., Ltd – sequence: 1 fullname: Yano, Takashi organization: Medical Affairs Department, Mochida Pharmaceutical Co., Ltd – sequence: 1 fullname: Kanda, Shingo organization: Clinical Development Planning and Management Department, Mochida Pharmaceutical Co., Ltd |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37532570$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkstuGyEUhkdVqubSLvoCFctkMQnXAe9qJZOLlIultmuEZ8DGYiAFJoofqu9YbCdeVF1wONL5zv-jcziuDnzwuqq-InjOGEMXK5XPG4oI-1AdISFgTQQnByUntOSUi8PqOKUVhIQwhj9Vh4QzghmHR9Wf1i-V73QPZjH0Y5dt8CAY0M6m9ZWO9qVUpj7b-s4bp4ZB5RDX4EFnNQ_OZp2AMllH8BSVA9N-sN6mHNW7jAKP4UU78EM7U7fD6JI1a-sX4NYulm4NZmO0xhaP4gfavFw70KaN3nWIhd7pnD48XtUYocnZ5-qjUS7pL2_3SfXruv15eVvfP93cXU7v667hNNeK8LmADRedMRQygYnoEYZz1GtqjKJUsX5CFSGb02tuBNcNI73BvBGYd-SkOt3pPsfwe9Qpy8GmTjunvA5jklhQ1rAGE1rQb2_oOB90L5-jHVRcy_cRF-BsB3QxpBS12SMIys36ZFmf3K6vsBf_sJ3N2yGUmVr3346bXUfxtp1ywTvrtVyFMfoyIalfeR-GtZIYYiLLD4AIS4iERBPMS6ATiieCNrwofd8prVJWC71_pYrZdk5vPQmUpb3Erfm-1C1VlNqTv64dymo |
| CitedBy_id | crossref_primary_10_1016_j_plipres_2024_101318 crossref_primary_10_1093_cvr_cvae007 crossref_primary_10_7759_cureus_81104 crossref_primary_10_1016_j_afres_2025_100745 crossref_primary_10_3390_nu16091354 |
| Cites_doi | 10.2337/db19-0550 10.1016/j.prostaglandins.2014.03.001 10.1056/NEJMoa1812792 10.1016/j.atherosclerosis.2013.09.023 10.5551/jat.50658 10.1016/j.nut.2018.10.026 10.1016/j.ijcard.2014.08.055 10.1016/j.jacl.2017.01.017 10.1093/intimm/dxz001 10.1039/C7FO00403F 10.1248/bpb1978.11.251 10.1253/circj.CJ-20-0199 10.5551/jat.52373 10.1016/j.jacl.2022.06.007 10.1093/carcin/bgy117 10.1016/j.atherosclerosis.2016.05.001 10.1016/S0140-6736(07)60527-3 10.1080/00325481.2021.1921491 10.1161/CIRCRESAHA.119.315506 10.1017/S0007114500002154 10.1016/j.plefa.2013.03.010 10.1186/s12944-017-0589-0 10.5551/jat.63727 10.3390/biom12020242 10.1002/cpdd.1177 10.1097/MCO.0000000000000896 10.1161/hh2101.099268 10.1038/s41467-022-30621-z 10.1016/j.jacl.2022.09.002 10.1084/jem.20132011 10.1096/fj.13-236224 10.1111/all.13297 10.1111/j.1365-2125.2012.04374.x 10.1096/fba.2019-00061 10.1253/circj.CJ-11-0941 10.1038/srep09750 10.1016/j.jaci.2017.09.053 10.1016/S0021-9258(18)64849-5 10.2169/internalmedicine.7336-21 |
| ContentType | Journal Article |
| Copyright | This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. |
| Copyright_xml | – notice: This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. |
| CorporateAuthor | Clinical Development Planning and Management Department RIKEN Center for Integrative Medical Sciences Dentistry and Pharmaceutical Sciences Laboratory for Metabolomics Mochida Pharmaceutical Co Graduate School of Medical Life Science Division of Physiological Chemistry and Metabolism Graduate School of Pharmaceutical Sciences Department of Cardiovascular Medicine Keio University Department of General Internal Medicine Clinical Research Department Yokohama City University Medical Affairs Department Okayama University Graduate School of Medicine Kawasaki Medical School Ltd |
| CorporateAuthor_xml | – name: Laboratory for Metabolomics – name: Yokohama City University – name: Clinical Research Department – name: RIKEN Center for Integrative Medical Sciences – name: Graduate School of Pharmaceutical Sciences – name: Clinical Development Planning and Management Department – name: Department of General Internal Medicine – name: Mochida Pharmaceutical Co – name: Department of Cardiovascular Medicine – name: Okayama University Graduate School of Medicine – name: Division of Physiological Chemistry and Metabolism – name: Dentistry and Pharmaceutical Sciences – name: Ltd – name: Kawasaki Medical School – name: Graduate School of Medical Life Science – name: Medical Affairs Department – name: Keio University |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.5551/jat.64135 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1880-3873 |
| EndPage | 1949 |
| ExternalDocumentID | 37532570 10_5551_jat_64135 ex7domya_2023_003012_018_1927_19494298467 article_jat_30_12_30_64135_article_char_en |
| Genre | Randomized Controlled Trial Journal Article |
| GroupedDBID | --- .55 29J 2WC 53G 5GY 5VS AAFWJ ACGFO ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK DU5 E3Z F5P GX1 HYE JMI JSF JSH KQ8 OK1 OVT P6G RJT RNS RPM RZJ TR2 X7M 3O- TKC AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c674t-a37b80678cff4058238d120b1de4ffa44a5d94a334a33de7f87e653df276827c3 |
| ISSN | 1340-3478 1880-3873 |
| IngestDate | Fri Jul 11 01:45:23 EDT 2025 Mon Jul 21 06:01:04 EDT 2025 Tue Jul 01 02:27:14 EDT 2025 Thu Apr 24 22:56:24 EDT 2025 Thu Jul 10 16:15:05 EDT 2025 Wed Sep 03 06:30:38 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Inflammation MND-2119 Metablolite Eicosapentaenoic acid |
| Language | English |
| License | https://creativecommons.org/licenses/by-nc-sa/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c674t-a37b80678cff4058238d120b1de4ffa44a5d94a334a33de7f87e653df276827c3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jat/30/12/30_64135/_article/-char/en |
| PMID | 37532570 |
| PQID | 2845656234 |
| PQPubID | 23479 |
| PageCount | 23 |
| ParticipantIDs | proquest_miscellaneous_2845656234 pubmed_primary_37532570 crossref_primary_10_5551_jat_64135 crossref_citationtrail_10_5551_jat_64135 medicalonline_journals_ex7domya_2023_003012_018_1927_19494298467 jstage_primary_article_jat_30_12_30_64135_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-Dec-01 |
| PublicationDateYYYYMMDD | 2023-12-01 |
| PublicationDate_xml | – month: 12 year: 2023 text: 2023-Dec-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | Journal of Atherosclerosis and Thrombosis |
| PublicationTitleAlternate | JAT |
| PublicationYear | 2023 |
| Publisher | Japan Atherosclerosis Society |
| Publisher_xml | – name: Japan Atherosclerosis Society |
| References | 6) Ninomiya T, Nagata M, Hata J, Hirakawa Y, Ozawa M, Yoshida D, Ohara T, Kishimoto H, Mukai N, Fukuhara M, Kitazono T, Kiyohara Y: Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. Atherosclerosis, 2013; 231: 261-267 39) Langlois PL, D'Aragon F, Hardy G, Manzanares W: Omega-3 polyunsaturated fatty acids in critically ill patients with acute respiratory distress syndrome: A systematic review and meta-analysis. Nutrition, 2019; 61: 84-92 2) Honda T, Chen S, Hata J, Shibata M, Furuta Y, Oishi E, Sakata S, Kitazono T, Ninomiya T: Changes in the Eicosapentaenoic Acid to Arachidonic Acid Ratio in Serum over 10 Years in a Japanese Community: The Hisayama Study. J Atheroscler Thromb, 2023; 30: 589-600 13) Qin Y, Nyheim H, Haram EM, Moritz JM, Hustvedt SO: A novel self-micro-emulsifying delivery system (SMEDS) formulation significantly improves the fasting absorption of EPA and DHA from a single dose of an omega-3 ethyl ester concentrate. Lipids Health Dis, 2017; 16: 204 12) Lopez-Toledano MA, Thorsteinsson T, Daak AA, Maki KC, Johns C, Rabinowicz AL, Sancilio FD: Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid TechnologiesTM (ALT®)-based formulation. J Clin Lipidol, 2017; 11: 394-405 26) Schuchardt JP, Schneider I, Willenberg I, Yang J, Hammock BD, Hahn A, Schebb NH: Increase of EPA-derived hydroxy, epoxy and dihydroxy fatty acid levels in human plasma after a single dose of long-chain omega-3 PUFA. Prostaglandins Other Lipid Mediat, 2014; 109-111: 23-31 20) Endo J, Sano M, Isobe Y, Fukuda K, Kang JX, Arai H, Arita M: 18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling. J Exp Med, 2014; 211: 1673-1687 29) Sugizaki Y, Otake H, Kuroda K, Kawamori H, Toba T, Nagasawa A, Takeshige R, Nakano S, Matsuoka Y, Tanimura K, Takahashi Y, Fukuyama Y, Hirata KI: Concomitant Use of Rosuvastatin and Eicosapentaenoic Acid Significantly Prevents Native Coronary Atherosclerotic Progression in Patients With In-Stent Neoatherosclerosis. Circ J, 2020; 84: 1826-1836 4) Domei T, Yokoi H, Kuramitsu S, Soga Y, Arita T, Ando K, Shirai S, Kondo K, Sakai K, Goya M, Iwabuchi M, Ueeda M, Nobuyoshi M: Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J, 2012; 76: 423-429 22) Ostermann AI and Schebb NH: Effects of omega-3 fatty acid supplementation on the pattern of oxylipins: a short review about the modulation of hydroxy-, dihydroxy-, and epoxy-fatty acids. Food Funct, 2017; 8: 2355-2367 19) Salic K, Morrison MC, Verschuren L, Wielinga PY, Wu L, Kleemann R, Gjorstrup P, Kooistra T: Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis, 2016; 250: 158-165 17) Ishihara T, Yoshida M and Arita M: Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis. Int Immunol, 2019; 31: 559-567 28) Doi M, Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, Nakayama R, Takagi W, Takeda K, Hirohata S, Ito H: Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. Int J Cardiol, 2014; 176: 577-582 34) Saika A, Nagatake T, Kishino S, Park SB, Honda T, Matsumoto N, Shimojou M, Morimoto S, Tiwari P, Node E, Hirata SI, Hosomi K, Kabashima K, Ogawa J, Kunisawa J: 17(S),18(R)-epoxyeicosatetraenoic acid generated by cytochrome P450 BM-3 from Bacillus megaterium inhibits the development of contact hypersensitivity via G-protein-coupled receptor 40-mediated neutrophil suppression. FASEB Bioadv, 2020; 2: 59-71 38) Singer P and Calder PC: The role of omega-3 polyunsaturated fatty acids in the intensive care unit. Curr Opin Clin Nutr Metab Care, 2023; 26: 129-137 9) Mori T, Murasaki K, Hayashi K, Yokoyama Y: Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study. J Clin Lipidol, 2022; 16: 704-714 8) Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med, 2019; 380: 11-22 24) Folch J, Lees M and Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem, 1957; 226: 497-509 37) Fleming I: Cytochrome p450 and vascular homeostasis. Circ Res, 2001; 89: 753-762 33) Nagatake T, Shiogama Y, Inoue A, Kikuta J, Honda T, Tiwari P, Kishi T, Yanagisawa A, Isobe Y, Matsumoto N, Shimojou M, Morimoto S, Suzuki H, Hirata SI, Steneberg P, Edlund H, Aoki J, Arita M, Kiyono H, Yasutomi Y, Ishii M, Kabashima K, Kunisawa J: The 17,18-epoxyeicosatetraenoic acid-G protein-coupled receptor 40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques. J Allergy Clin Immunol, 2018; 142: 470-484.e12 16) Crupi R and Cuzzocrea S: Role of EPA in Inflammation: Mechanisms, Effects, and Clinical Relevance. Biomolecules, 2022; 12: 242 21) Moriyama H, Endo J, Kataoka M, Shimanaka Y, Kono N, Sugiura Y, Goto S, Kitakata H, Hiraide T, Yoshida N, Isobe S, Yamamoto T, Shirakawa K, Anzai A, Katsumata Y, Suematsu M, Kosaki K, Fukuda K, Arai H, Sano M: Omega-3 fatty acid epoxides produced by PAF-AH2 in mast cells regulate pulmonary vascular remodeling. Nat Commun, 2022; 13: 3013 32) Kunisawa J, Arita M, Hayasaka T, Harada T, Iwamoto R, Nagasawa R, Shikata S, Nagatake T, Suzuki H, Hashimoto E, Kurashima Y, Suzuki Y, Arai H, Setou M, Kiyono H: Dietary ω3 fatty acid exerts anti-allergic effect through the conversion to 17,18-epoxyeicosatetraenoic acid in the gut. Sci Rep, 2015; 5: 9750 3) Shojima Y, Ueno Y, Tanaka R, Yamashiro K, Miyamoto N, Hira K, Kurita N, Nakajima S, Urabe T, Hattori N: Eicosapentaenoic-to-Arachidonic Acid Ratio Predicts Mortality and Recurrent Vascular Events in Ischemic Stroke Patients. J Atheroscler Thromb, 2020; 27: 969-977 25) Ishiguro J, Tada T, Ogihara T, Ohzawa N, Murakami K, Kosuzume H: Metabolic disposition of ethyl eicosapentaenoate and its metabolites in rats and dogs. J Pharmacobiodyn, 1988; 11: 251-261 30) Suzumura A, Kaneko H, Funahashi Y, Takayama K, Nagaya M, Ito S, Okuno T, Hirakata T, Nonobe N, Kataoka K, Shimizu H, Namba R, Yamada K, Ye F, Ozawa Y, Yokomizo T, Terasaki H: n-3 Fatty Acid and Its Metabolite 18-HEPE Ameliorate Retinal Neuronal Cell Dysfunction by Enhancing Muller BDNF in Diabetic Retinopathy. Diabetes, 2020; 69: 724-735 14) Mori T, Murasaki K and Yokoyama Y: Pharmacokinetics of Single and Multiple Oral Administration of a Self-emulsifying Formulation of Highly Purified Eicosapentaenoic Acid Ethyl Ester (MND-2119) Compared With the Nonself-emulsifying Formulation in Healthy Male Subjects. Clin Pharmacol Drug Dev, 2022; 12: 107-115 1) Nelson JR, Budoff MJ, Wani OR, Le V, Patel DK, Nelson A, Nemiroff RL: EPA's pleiotropic mechanisms of action: a narrative review. Postgrad Med, 2021; 133: 651-664 15) Calder PC: Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol, 2013; 75: 645-662 5) Niwa K, Tanaka A, Funakubo H, Otsuka S, Yoshioka N, Kudo N, Tobe A, Sakakibara K, Miki Y, Kataoka T, Furusawa K, Ishii H, Murohara T: The Influence of Eicosapentaenoic Acid to Arachidonic Acid Ratio on Long-term Cardiovascular Events Following Percutaneous Coronary Intervention. Intern Med, 2021; 60: 3865-3871 7) Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098 10) Mori T, Murasaki K and Yokoyama Y: Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study. J Clin Lipidol, 2022; 16: 737-746 18) Watanabe Y and Tatsuno I: Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved. J Atheroscler Thromb, 2020; 27: 183-198 31) Li J, Chen CY, Arita M, Kim K, Li X, Zhang H, Kang JX: An omega-3 polyunsaturated fatty acid derivative, 18-HEPE, protects against CXCR4-associated melanoma metastasis. Carcinogenesis, 2018; 39: 1380-1388 23) Burdge GC, Wright P, Jones AE, Wootton SA: A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction. Br J Nutr, 2000; 84: 781-787 36) Mochimaru T, Fukunaga K, Miyata J, Matsusaka M, Masaki K, Kabata H, Ueda S, Suzuki Y, Goto T, Urabe D, Inoue M, Isobe Y, Arita M, Betsuyaku T: 12-OH-17,18-Epoxyeicosatetraenoic acid alleviates eosinophilic airway inflammation in murine lungs. Allergy, 2018; 73: 369-378 27) Souza PR, Marques RM, Gomez EA, Colas RA, De Matteis R, Zak A, Patel M, Collier DJ, Dalli J: Enriched Marine Oil Supplements Increase Peripheral Blood Specialized Pro-Resolving Mediators Concentrations and Reprogram Host Immune Responses: A Randomized Double-Blind Placebo-Controlled Study. Circ Res, 2020; 126: 75-90 11) Schuchardt JP and Hahn A: Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids, 2013; 89: 1-8 35) Kubota T, Arita M, Isobe Y, Iwamoto R, Goto T, Yoshioka T, 22 23 24 25 26 27 28 29 30 31 10 32 11 33 12 34 13 35 14 36 15 37 16 38 17 39 18 19 1 2 3 4 5 6 7 8 9 20 21 |
| References_xml | – reference: 17) Ishihara T, Yoshida M and Arita M: Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis. Int Immunol, 2019; 31: 559-567 – reference: 8) Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med, 2019; 380: 11-22 – reference: 26) Schuchardt JP, Schneider I, Willenberg I, Yang J, Hammock BD, Hahn A, Schebb NH: Increase of EPA-derived hydroxy, epoxy and dihydroxy fatty acid levels in human plasma after a single dose of long-chain omega-3 PUFA. Prostaglandins Other Lipid Mediat, 2014; 109-111: 23-31 – reference: 39) Langlois PL, D'Aragon F, Hardy G, Manzanares W: Omega-3 polyunsaturated fatty acids in critically ill patients with acute respiratory distress syndrome: A systematic review and meta-analysis. Nutrition, 2019; 61: 84-92 – reference: 38) Singer P and Calder PC: The role of omega-3 polyunsaturated fatty acids in the intensive care unit. Curr Opin Clin Nutr Metab Care, 2023; 26: 129-137 – reference: 14) Mori T, Murasaki K and Yokoyama Y: Pharmacokinetics of Single and Multiple Oral Administration of a Self-emulsifying Formulation of Highly Purified Eicosapentaenoic Acid Ethyl Ester (MND-2119) Compared With the Nonself-emulsifying Formulation in Healthy Male Subjects. Clin Pharmacol Drug Dev, 2022; 12: 107-115 – reference: 23) Burdge GC, Wright P, Jones AE, Wootton SA: A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction. Br J Nutr, 2000; 84: 781-787 – reference: 11) Schuchardt JP and Hahn A: Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids, 2013; 89: 1-8 – reference: 13) Qin Y, Nyheim H, Haram EM, Moritz JM, Hustvedt SO: A novel self-micro-emulsifying delivery system (SMEDS) formulation significantly improves the fasting absorption of EPA and DHA from a single dose of an omega-3 ethyl ester concentrate. Lipids Health Dis, 2017; 16: 204 – reference: 9) Mori T, Murasaki K, Hayashi K, Yokoyama Y: Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study. J Clin Lipidol, 2022; 16: 704-714 – reference: 28) Doi M, Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, Nakayama R, Takagi W, Takeda K, Hirohata S, Ito H: Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. Int J Cardiol, 2014; 176: 577-582 – reference: 29) Sugizaki Y, Otake H, Kuroda K, Kawamori H, Toba T, Nagasawa A, Takeshige R, Nakano S, Matsuoka Y, Tanimura K, Takahashi Y, Fukuyama Y, Hirata KI: Concomitant Use of Rosuvastatin and Eicosapentaenoic Acid Significantly Prevents Native Coronary Atherosclerotic Progression in Patients With In-Stent Neoatherosclerosis. Circ J, 2020; 84: 1826-1836 – reference: 12) Lopez-Toledano MA, Thorsteinsson T, Daak AA, Maki KC, Johns C, Rabinowicz AL, Sancilio FD: Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid TechnologiesTM (ALT®)-based formulation. J Clin Lipidol, 2017; 11: 394-405 – reference: 15) Calder PC: Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol, 2013; 75: 645-662 – reference: 20) Endo J, Sano M, Isobe Y, Fukuda K, Kang JX, Arai H, Arita M: 18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling. J Exp Med, 2014; 211: 1673-1687 – reference: 30) Suzumura A, Kaneko H, Funahashi Y, Takayama K, Nagaya M, Ito S, Okuno T, Hirakata T, Nonobe N, Kataoka K, Shimizu H, Namba R, Yamada K, Ye F, Ozawa Y, Yokomizo T, Terasaki H: n-3 Fatty Acid and Its Metabolite 18-HEPE Ameliorate Retinal Neuronal Cell Dysfunction by Enhancing Muller BDNF in Diabetic Retinopathy. Diabetes, 2020; 69: 724-735 – reference: 6) Ninomiya T, Nagata M, Hata J, Hirakawa Y, Ozawa M, Yoshida D, Ohara T, Kishimoto H, Mukai N, Fukuhara M, Kitazono T, Kiyohara Y: Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. Atherosclerosis, 2013; 231: 261-267 – reference: 5) Niwa K, Tanaka A, Funakubo H, Otsuka S, Yoshioka N, Kudo N, Tobe A, Sakakibara K, Miki Y, Kataoka T, Furusawa K, Ishii H, Murohara T: The Influence of Eicosapentaenoic Acid to Arachidonic Acid Ratio on Long-term Cardiovascular Events Following Percutaneous Coronary Intervention. Intern Med, 2021; 60: 3865-3871 – reference: 21) Moriyama H, Endo J, Kataoka M, Shimanaka Y, Kono N, Sugiura Y, Goto S, Kitakata H, Hiraide T, Yoshida N, Isobe S, Yamamoto T, Shirakawa K, Anzai A, Katsumata Y, Suematsu M, Kosaki K, Fukuda K, Arai H, Sano M: Omega-3 fatty acid epoxides produced by PAF-AH2 in mast cells regulate pulmonary vascular remodeling. Nat Commun, 2022; 13: 3013 – reference: 35) Kubota T, Arita M, Isobe Y, Iwamoto R, Goto T, Yoshioka T, Urabe D, Inoue M, Arai H: Eicosapentaenoic acid is converted via ω-3 epoxygenation to the anti-inflammatory metabolite 12-hydroxy-17,18-epoxyeicosatetraenoic acid. FASEB J, 2014; 28: 586-593 – reference: 34) Saika A, Nagatake T, Kishino S, Park SB, Honda T, Matsumoto N, Shimojou M, Morimoto S, Tiwari P, Node E, Hirata SI, Hosomi K, Kabashima K, Ogawa J, Kunisawa J: 17(S),18(R)-epoxyeicosatetraenoic acid generated by cytochrome P450 BM-3 from Bacillus megaterium inhibits the development of contact hypersensitivity via G-protein-coupled receptor 40-mediated neutrophil suppression. FASEB Bioadv, 2020; 2: 59-71 – reference: 10) Mori T, Murasaki K and Yokoyama Y: Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study. J Clin Lipidol, 2022; 16: 737-746 – reference: 32) Kunisawa J, Arita M, Hayasaka T, Harada T, Iwamoto R, Nagasawa R, Shikata S, Nagatake T, Suzuki H, Hashimoto E, Kurashima Y, Suzuki Y, Arai H, Setou M, Kiyono H: Dietary ω3 fatty acid exerts anti-allergic effect through the conversion to 17,18-epoxyeicosatetraenoic acid in the gut. Sci Rep, 2015; 5: 9750 – reference: 19) Salic K, Morrison MC, Verschuren L, Wielinga PY, Wu L, Kleemann R, Gjorstrup P, Kooistra T: Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis, 2016; 250: 158-165 – reference: 18) Watanabe Y and Tatsuno I: Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved. J Atheroscler Thromb, 2020; 27: 183-198 – reference: 33) Nagatake T, Shiogama Y, Inoue A, Kikuta J, Honda T, Tiwari P, Kishi T, Yanagisawa A, Isobe Y, Matsumoto N, Shimojou M, Morimoto S, Suzuki H, Hirata SI, Steneberg P, Edlund H, Aoki J, Arita M, Kiyono H, Yasutomi Y, Ishii M, Kabashima K, Kunisawa J: The 17,18-epoxyeicosatetraenoic acid-G protein-coupled receptor 40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques. J Allergy Clin Immunol, 2018; 142: 470-484.e12 – reference: 37) Fleming I: Cytochrome p450 and vascular homeostasis. Circ Res, 2001; 89: 753-762 – reference: 24) Folch J, Lees M and Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem, 1957; 226: 497-509 – reference: 36) Mochimaru T, Fukunaga K, Miyata J, Matsusaka M, Masaki K, Kabata H, Ueda S, Suzuki Y, Goto T, Urabe D, Inoue M, Isobe Y, Arita M, Betsuyaku T: 12-OH-17,18-Epoxyeicosatetraenoic acid alleviates eosinophilic airway inflammation in murine lungs. Allergy, 2018; 73: 369-378 – reference: 16) Crupi R and Cuzzocrea S: Role of EPA in Inflammation: Mechanisms, Effects, and Clinical Relevance. Biomolecules, 2022; 12: 242 – reference: 27) Souza PR, Marques RM, Gomez EA, Colas RA, De Matteis R, Zak A, Patel M, Collier DJ, Dalli J: Enriched Marine Oil Supplements Increase Peripheral Blood Specialized Pro-Resolving Mediators Concentrations and Reprogram Host Immune Responses: A Randomized Double-Blind Placebo-Controlled Study. Circ Res, 2020; 126: 75-90 – reference: 1) Nelson JR, Budoff MJ, Wani OR, Le V, Patel DK, Nelson A, Nemiroff RL: EPA's pleiotropic mechanisms of action: a narrative review. Postgrad Med, 2021; 133: 651-664 – reference: 2) Honda T, Chen S, Hata J, Shibata M, Furuta Y, Oishi E, Sakata S, Kitazono T, Ninomiya T: Changes in the Eicosapentaenoic Acid to Arachidonic Acid Ratio in Serum over 10 Years in a Japanese Community: The Hisayama Study. J Atheroscler Thromb, 2023; 30: 589-600 – reference: 3) Shojima Y, Ueno Y, Tanaka R, Yamashiro K, Miyamoto N, Hira K, Kurita N, Nakajima S, Urabe T, Hattori N: Eicosapentaenoic-to-Arachidonic Acid Ratio Predicts Mortality and Recurrent Vascular Events in Ischemic Stroke Patients. J Atheroscler Thromb, 2020; 27: 969-977 – reference: 25) Ishiguro J, Tada T, Ogihara T, Ohzawa N, Murakami K, Kosuzume H: Metabolic disposition of ethyl eicosapentaenoate and its metabolites in rats and dogs. J Pharmacobiodyn, 1988; 11: 251-261 – reference: 4) Domei T, Yokoi H, Kuramitsu S, Soga Y, Arita T, Ando K, Shirai S, Kondo K, Sakai K, Goya M, Iwabuchi M, Ueeda M, Nobuyoshi M: Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J, 2012; 76: 423-429 – reference: 7) Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098 – reference: 31) Li J, Chen CY, Arita M, Kim K, Li X, Zhang H, Kang JX: An omega-3 polyunsaturated fatty acid derivative, 18-HEPE, protects against CXCR4-associated melanoma metastasis. Carcinogenesis, 2018; 39: 1380-1388 – reference: 22) Ostermann AI and Schebb NH: Effects of omega-3 fatty acid supplementation on the pattern of oxylipins: a short review about the modulation of hydroxy-, dihydroxy-, and epoxy-fatty acids. Food Funct, 2017; 8: 2355-2367 – ident: 30 doi: 10.2337/db19-0550 – ident: 26 doi: 10.1016/j.prostaglandins.2014.03.001 – ident: 8 doi: 10.1056/NEJMoa1812792 – ident: 6 doi: 10.1016/j.atherosclerosis.2013.09.023 – ident: 18 doi: 10.5551/jat.50658 – ident: 39 doi: 10.1016/j.nut.2018.10.026 – ident: 28 doi: 10.1016/j.ijcard.2014.08.055 – ident: 12 doi: 10.1016/j.jacl.2017.01.017 – ident: 17 doi: 10.1093/intimm/dxz001 – ident: 22 doi: 10.1039/C7FO00403F – ident: 25 doi: 10.1248/bpb1978.11.251 – ident: 29 doi: 10.1253/circj.CJ-20-0199 – ident: 3 doi: 10.5551/jat.52373 – ident: 9 doi: 10.1016/j.jacl.2022.06.007 – ident: 31 doi: 10.1093/carcin/bgy117 – ident: 19 doi: 10.1016/j.atherosclerosis.2016.05.001 – ident: 7 doi: 10.1016/S0140-6736(07)60527-3 – ident: 1 doi: 10.1080/00325481.2021.1921491 – ident: 27 doi: 10.1161/CIRCRESAHA.119.315506 – ident: 23 doi: 10.1017/S0007114500002154 – ident: 11 doi: 10.1016/j.plefa.2013.03.010 – ident: 13 doi: 10.1186/s12944-017-0589-0 – ident: 2 doi: 10.5551/jat.63727 – ident: 16 doi: 10.3390/biom12020242 – ident: 14 doi: 10.1002/cpdd.1177 – ident: 38 doi: 10.1097/MCO.0000000000000896 – ident: 37 doi: 10.1161/hh2101.099268 – ident: 21 doi: 10.1038/s41467-022-30621-z – ident: 10 doi: 10.1016/j.jacl.2022.09.002 – ident: 20 doi: 10.1084/jem.20132011 – ident: 35 doi: 10.1096/fj.13-236224 – ident: 36 doi: 10.1111/all.13297 – ident: 15 doi: 10.1111/j.1365-2125.2012.04374.x – ident: 34 doi: 10.1096/fba.2019-00061 – ident: 4 doi: 10.1253/circj.CJ-11-0941 – ident: 32 doi: 10.1038/srep09750 – ident: 33 doi: 10.1016/j.jaci.2017.09.053 – ident: 24 doi: 10.1016/S0021-9258(18)64849-5 – ident: 5 doi: 10.2169/internalmedicine.7336-21 |
| SSID | ssj0033552 ssib002822083 |
| Score | 2.3911755 |
| Snippet | Aims: MND-2119 is a novel once-daily dose self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (EPA-E) and is approved as an... MND-2119 is a novel once-daily dose self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (EPA-E) and is approved as an... |
| SourceID | proquest pubmed crossref medicalonline jstage |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1927 |
| SubjectTerms | Administration, Oral Adult Anti-Inflammatory Agents Docosahexaenoic Acids Eicosapentaenoic Acid Esters Fatty Acids Humans Inflammation Male Metablolite MND-2119 |
| Title | Enhanced Production of EPA-Derived Anti-Inflammatory Metabolites after Oral Administration of a Novel Self-Emulsifying Highly Purified EPA Ethyl Ester Formulation (MND-2119) |
| URI | https://www.jstage.jst.go.jp/article/jat/30/12/30_64135/_article/-char/en http://mol.medicalonline.jp/library/journal/download?GoodsID=ex7domya/2023/003012/018&name=1927-1949e https://www.ncbi.nlm.nih.gov/pubmed/37532570 https://www.proquest.com/docview/2845656234 |
| Volume | 30 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Atherosclerosis and Thrombosis, 2023/12/01, Vol.30(12), pp.1927-1949 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGQAgJIW6DcpNBPAxVGW2uzRsT6xho7SbRSX2zHMcRYW2CmmSi_Cd-A3-Nc2wnTVmRBg-1msRxEp0vx9-Jz4WQ1zitBb6bWI4QgeUKblvhQHCLR6AMB7AdexgoPBr7R2fup6k33dr61fJaqspoT_zYGFfyP1KFfSBXjJL9B8k2g8IO-A_yhRYkDO2VZDzMvugF_FOdt9WQv-HpvnUA17-AI_tZmVofswQEP9cL6iNZguAx9LgwFcJPMEh_PYuuDpsc5xdyBupklljDeTUrUh0Uhb4hs2X3tFqkCTJYuB76zS9n3SGmXegeAg82VcGQwI7GBxZmeKs_OlymwoqF5gU8HbRpYbw6F_k8ws0GE-kyL1QN4u4kX1TNZ2yuvRk_w-Od56sFgnMe8SU3Jxyli3xZnaeNkuOq5Hh3At2gS_vbh-20_Ei0ugbtg9mBtYqUG_YZHW_WfgyW7ZbGBoYbbJpKPKCSqoRBuefDRO-t5svaR2B8wg7Pjo_ZZDidXCPXbbBTcGb4MG18jBwgc2q5vb4lndoKh37bDLxGiG58BZsAkz3cnut1Op0v5e_mj6JBk7vkjhEa3ddgvEe2ZHaf3BwZD40H5GeNSbrCJM0T2sIkvYRJ2sIkVZikiEm6jkkchlOFSfonJqnGJK0xidejCpNUYZK2MEl3a0S-eUjODoeT90eWKQliCT9wS4s7QTRAgiWSBEyNARDOuG_3on4s3SThrsu9OHS54-AvlkEyCKTvOXFig1ltB8LZIdtZnsnHhMLMI4C2hcIOMQ2lDLkfShH7Mgnsnuj1OmS3lgsTJl8-lm2ZMbCbUYQMRMiUCDvkVdP1m04Ss6lTqIXbdDF6Q3VxwBa3sVV9m0MYegmarkPereGBGSVUMPk9iPP5kjN8PZj6wGGzXn_AENfQuCEQTrQxOuRlDSEGMwguC_JM5lXBgKCiVWc7boc80thqbtEJPAfrXD65wtlPya3VO_qMbJeLSj4Hxl5GL9Rb8Rscx_D1 |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enhanced+Production+of+EPA-Derived+Anti-Inflammatory+Metabolites+after+Oral+Administration+of+a+Novel+Self-Emulsifying+Highly+Purified+EPA+Ethyl+Ester+Formulation+%28MND-2119%29&rft.jtitle=Journal+of+atherosclerosis+and+thrombosis&rft.au=Miyoshi%2C+Toru&rft.au=Naoe%2C+Satoko&rft.au=Wakabayashi%2C+Hiroyuki&rft.au=Yano%2C+Takashi&rft.date=2023-12-01&rft.issn=1880-3873&rft.eissn=1880-3873&rft.volume=30&rft.issue=12&rft.spage=1927&rft_id=info:doi/10.5551%2Fjat.64135&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1340-3478&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1340-3478&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1340-3478&client=summon |